Therapy News and Research

RSS

Egg secretions from a worm may be useful in gene therapy

Egg secretions from a worm that causes a deadly human disease may prove useful in gene therapy, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

8 Sep 2008

New coating for urinary catheters reduce infection risk

A new coating for urinary catheters could reduce the risk of infection, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

8 Sep 2008

Vaginal rings provide new HIV protection for women

Vaginal rings, similar to those used for contraception and hormone replacement therapy, could protect women from sexually-transmitted HIV, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

8 Sep 2008

The Cancer Genome Atlas reports first results

The Cancer Genome Atlas (TCGA) has reported results from its first comprehensive study which focused on the deadly brain cancer glioblastoma.

8 Sep 2008

New treatment for diabetics identified

Some of the most serious health complications associated with diabetes could be prevented or delayed by taking a widely available cholesterol-lowering drug which has already been on the market for three decades, new research has shown.

8 Sep 2008

Once a week treatment for type 2 diabetes in the pipeline

Canadian researchers have found that a weekly treatment for type 2 diabetes has proved safe and effective for patients.

8 Sep 2008

Myalgic encephalomyelitis sufferers rely on aternative medicines

More than a third of patients with long-term fatigue conditions like Myalgic Encephalomyelitis (ME) believe complementary and alternative medicines (CAMs) are more effective than traditional medicine in treating their illness, research launched at the British Pharmaceutical Conference (BPC) in Manchester reveals.

7 Sep 2008

Atomic structure of the mammalian "fatty acid factory" determined

Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in Science magazine.

7 Sep 2008

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects.

7 Sep 2008

Black women less likely than white women to receive follow-up treatments after breast cancer surgery

Black women who undergo a lumpectomy surgery to treat early-stage breast cancer are less likely than their white counterparts to receive the recommended follow-up radiation therapy treatments, according to study released on Wednesday, Reuters/Boston Globe reports. Standard care after a lumpectomy includes a series of radiation treatments to ensure that all cancerous cells have been treated.

5 Sep 2008

FDA approves DNA test to measure hepatitis B viral load

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.

5 Sep 2008

Heavy snorers at increased risk of stroke

University of Sydney researchers have found that heavy snorers have a higher risk of cholesterol plaque in the neck arteries, leading to an increased risk of stroke.

4 Sep 2008

$FDA approves Medtronic software update that will help detect fractures in cardiac defibrillator leads$

FDA approves Medtronic software update that will help detect fractures in cardiac defibrillator leads

The U.S. Food and Drug Administration today announced approval of a software update from Medtronic that will help detect fractures of the company's Sprint Fidelis cardiac defibrillator lead.

4 Sep 2008

FDA 'fast track' granted to BioMS Medical for lead drug, dirucotide for the treatment of multiple sclerosis

BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

4 Sep 2008

Celgene receives FDA 'fast track' for Amrubicin in small cell lung cancer after first-line chemotherapy

Celgene Corporation today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.

4 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Vimpat (lacosamide) approved in Europe

UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.

3 Sep 2008

MRSA breast infections controllable in nursing mothers, researchers find

Many nursing mothers who have been hospitalized for breast abscesses are afflicted with the "superbug" methicillin-resistant Staphylococcus aureus, or MRSA, but according to new research by UT Southwestern Medical Center physicians, conservative treatment can deal with the problem.

3 Sep 2008